1334922-97-2

Upstream product

• 696-63-9 4-Methoxybenzenethiol 
• 118738-91-3 1-(4-iodo-2,6-dimethylphenyl)ethanone 

Downstream Products

• 1334923-00-0 2-bromo-1-{4-[(4-methoxyphenyl)thio]-2,6-dimethylphenyl}ethanone 
• 1334923-02-2 4-{4-[(4-methoxyphenyl)thio]-2,6-dimethylphenyl}thiazol-2-amine 
• 1334923-04-4 2-bromo-1-(4-(4-methoxyphenylsulfonyl)-2,6-dimethylphenyl)ethanone 
• 1334923-05-5 4-(4-(4-methoxyphenylsulfonyl)-2,6-dimethylphenyl)thiazol-2-amine 
• 1334923-06-6 2-bromo-1-(4-(4-methoxyphenylsulfinyl)2,6-dimethylphenyl)ethanone 
• 1334923-07-7 C₁₈H₁₈N₂O₂S₂ 
• 1334921-71-9 N-(4-(4-(4-methoxyphenylsulfinyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide 

Relevant academic research and scientific papers

Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy

Highly expressed in cancer 1 (Hec1) plays an essential role in mitosis and is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function, thus any disruption of Hec1/Nek2 prote

IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases

Modulators Of HEC1 Activity And Methods Therefor

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.